A Single Blinded Study on the Effect of Saccharomyces Boulardii CNCM I-745 on Growth and Development in Preterm Infants
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
Immature gastrointestinal functions increase the risk of poor growth as well as nosocomial
infections and necrotizing enterocolitis (NEC) in the preterm infant. The effects of
probiotics on growth and development in premature infants have been investigated poorly.
Saccharomyces boulardii CNCM I-745 (S. boulardii) is a non-pathogenic probiotic yeast.
Prophylactic supplementation of S. boulardii at a dose of 50 mg/kg twice a day appeared to
bring preterm infants weight gain closer to that of intra-uterine growth rate, reduce feeding
intolerance, and had no adverse effects.